MA55735A - Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23 - Google Patents

Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23

Info

Publication number
MA55735A
MA55735A MA055735A MA55735A MA55735A MA 55735 A MA55735 A MA 55735A MA 055735 A MA055735 A MA 055735A MA 55735 A MA55735 A MA 55735A MA 55735 A MA55735 A MA 55735A
Authority
MA
Morocco
Prior art keywords
inhibitor
polytherapy
inhibitor based
based polytherapy
Prior art date
Application number
MA055735A
Other languages
English (en)
French (fr)
Inventor
Michele Luise Gerber
Heath Michael Guay
Neil Bradford Lineberry
Jorge Rodrigo Mora
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA55735A publication Critical patent/MA55735A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055735A 2019-04-17 2020-04-17 Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23 MA55735A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962835349P 2019-04-17 2019-04-17

Publications (1)

Publication Number Publication Date
MA55735A true MA55735A (fr) 2022-02-23

Family

ID=72837950

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055735A MA55735A (fr) 2019-04-17 2020-04-17 Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23

Country Status (5)

Country Link
US (1) US20230096620A1 (https=)
EP (1) EP3956358A4 (https=)
JP (2) JP7778567B2 (https=)
MA (1) MA55735A (https=)
WO (1) WO2020215019A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159633A1 (en) * 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2026058045A1 (en) * 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CA3255406A1 (en) * 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
WO2017106595A1 (en) * 2015-12-18 2017-06-22 Sciadonics, Inc. Lipid formulations containing bioactive fatty acids and a non-fatty acid anti-inflammatory agent
US10918716B2 (en) * 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
US20200253506A1 (en) * 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
AU2018256840A1 (en) * 2017-04-28 2019-11-07 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
US20230033021A1 (en) * 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Also Published As

Publication number Publication date
JP2022529929A (ja) 2022-06-27
US20230096620A1 (en) 2023-03-30
EP3956358A1 (en) 2022-02-23
EP3956358A4 (en) 2023-01-25
JP2025169256A (ja) 2025-11-12
WO2020215019A1 (en) 2020-10-22
JP7778567B2 (ja) 2025-12-02

Similar Documents

Publication Publication Date Title
MA54399A (fr) Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
EP3956358A4 (en) COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
EP3402500A4 (en) COMBINATION THERAPY OF ONCOLYTIC VIRUS AND CHECKPOINT INHIBITOR
EP3819300A4 (en) THERAPEUTIC COMPOSITION BASED ON BIOMARKERS
UA42295S (uk) Комп'ютер
EP3463405A4 (en) Adenovirus and immunomodulator combination therapy
EP3441495A4 (en) AUSTENITIC STAINLESS STEEL MATERIAL
EP4004677A4 (en) INDICATOR
EP3995553A4 (en) ISOCYANATE BASED ADHESIVE
EP4075258A4 (en) Display apparatus
EP3359150A4 (en) COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
EP4022596A4 (en) INDICATOR
EP3909068A4 (en) HAFNIUM OXIDE CORROSION INHIBITOR
EP3885377A4 (en) OLEFIN-BASED POLYMER
EP3824186A4 (en) SCROLL COMPRESSORS
EP3867898A4 (en) ANTI-COUNTERFEIT LABEL
EP4006633A4 (en) INDICATOR
EP3982415A4 (en) SHOWBOARD
EP3919579A4 (en) URETHANE-BASED ADHESIVE COMPOSITION
EP3919581A4 (en) URETHANE BASED ADHESIVE COMPOSITION
EP3957660A4 (en) OLEFIN-BASED POLYMER
EP3949444A4 (en) Display apparatus
EP3917319A4 (en) MICRO-ENCAPSULATED ACETAMIDE HERBICIDES
EP4100821A4 (en) INTERACTIVE DISPLAYS
EP3846200A4 (en) OLED DISPLAY DEVICE